Environmental

No disclosed R&D intensity or emissions-related metrics are provided, limiting evidence of peer-leading environmental management versus similarly regulated healthcare peers.

The absence of reported environmental capital allocation data makes it difficult to assess whether SOMN is ahead of peers on resource efficiency or climate-related disclosure.

With no direct environmental controversy or compliance data supplied, SOMN appears neither clearly advantaged nor structurally disadvantaged versus peers on environmental factors.

Social

The provided metrics do not include workforce, safety, product quality, or patient-related indicators, so SOMN cannot be shown to outperform peers on core social materiality.

Stock-based compensation at 0.44% of revenue suggests limited dilution pressure, but this is only a modest social governance signal versus peers rather than a clear advantage.

Without disclosure on employee retention, diversity, or customer harm events, SOMN’s social positioning remains broadly in line with peers but not demonstrably stronger.

Governance

Stock-based compensation at 0.44% of revenue is low, which supports better capital discipline than many peers with heavier equity-based pay structures.

Debt-to-equity of 1.95 and net debt-to-EBITDA of 5.22 indicate meaningful leverage, which weakens governance resilience relative to more conservatively financed peers.

The absence of disclosed board, audit, or controversy data prevents a stronger governance score, although the limited SBC burden partially offsets the leverage concern.

Overall Score

SOMN’s ESG profile is broadly average versus peers because limited disclosure and meaningful leverage offset a modest governance benefit from low stock-based compensation.

Score Driver: Meaningful Leverage Relative To Peers